Denis Drygin

5.1k citations

41 papers · 2.7k indexed · h-index 18

Impact in

Molecular Biology top 5%
- RNA modifications and cancer
- RNA and protein synthesis mechanisms
- DNA and Nucleic Acid Chemistry
- Advanced biosensing and bioanalysis techniques
- RNA Research and Splicing
- RNA Interference and Gene Delivery
- DNA Repair Mechanisms
Oncology top 5%
- Cancer-related Molecular Pathways

Papers in

Pathology and Forensic Medicine 10
- Cancer Mechanisms and Therapy 6
Molecular Biology 33
- RNA modifications and cancer 15
- RNA and protein synthesis mechanisms 6
- Ubiquitin and proteasome pathways 5
- DNA Repair Mechanisms 4
- PI3K/AKT/mTOR signaling in cancer 4
- DNA and Nucleic Acid Chemistry 4

Co-authors: William G. Rice Sean O’Brien Adam Siddiqui-Jain Ingrid Grummt Kenna Anderes Chris Proffitt Caroline B. Ho David M. Ryckman
Journals: Cancer Research (9 papers)Blood (4 papers)Molecular Cancer Therapeutics (3 papers)Bioorganic & Medicinal Chemistry Letters (3 papers)Clinical Cancer Research (2 papers)
Partner nations: United States Australia United Kingdom

In The Last Decade

Denis Drygin

40 papers receiving 2.7k citations

Peers

Countries citing papers authored by Denis Drygin

Since Specialization

Citations

This map shows the geographic impact of Denis Drygin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Denis Drygin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Denis Drygin more than expected).

Fields of papers citing papers by Denis Drygin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Denis Drygin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Denis Drygin. The network helps show where Denis Drygin may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Denis Drygin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Denis Drygin Line = papers co-authored together Denis Drygin links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	CX-5461 Preferentially Induces Top2α-Dependent DNA Breaks at Ribosomal DNA Loci Biomedicines ·Donald P. Cameron, C Papatheodorou, 胡长兵, Denis Drygin, Gretchen Poortinga, Grant A. McArthur, Nadine Hein, Ross D. Hannan, Kostya I. Panov	2024	4
2	Abstract PR004: Second generation RNA Polymerase I inhibitor PMR-116 targets ribsomal RNA synthesis to potently treat a broad spectrum of malignancies Molecular Cancer Therapeutics ·Rita Ferreira, Katherine M. Hannan, Kostya I. Panov, Hou Zhen-hui, Amee J. George, HamidIqil Naqvi, Morteza Rahmanpour, Eric Kusnadi, J. N. Pickoul, Mitchell G. Lawrence, Mustapha Haddach, Denis Drygin, Luc Furic, Ross D. Hannan, Nadine Hein	2024	1
3	Targeting RNA Polymerase I Transcription Activity in Osteosarcoma: Pre-Clinical Molecular and Animal Treatment Studies Biomedicines ·Chang Won Kang, Anneke C. Blackburn, Amos Hong Pheng Loh, Filip Izgi, Jian Yuan Goh, Nadine Hein, Denis Drygin, Christopher R. Parish, Ross D. Hannan, Katherine M. Hannan, Lucy A. Coupland	2023	3
4	RGLS4326 Increases Urinary PC1 and PC2 Levels in Individuals with Autosomal Dominant Polycystic Kidney Disease (ADPKD) Journal of the American Society of Nephrology ·Edmund Lee, Genovese Paolo Vincenzo, E. PAUL DURRENBERGER, S Neben, Esmée Braams, Neethu Mariya Mathew, Denis Drygin, Christopher J. Ward, Alan S.L. Yu, Vishal Patel	2021	3
5	The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer Clinical Cancer Research ·Richard J. Rebello, Eric Kusnadi, Donald P. Cameron, Helen Pearson, Rom Mit, Jennifer R. Devlin, Denis Drygin, Ashlee K. Clark, Laura H. Porter, John Pedersen, Shahneen Sandhu, Gail P. Risbridger, Richard B. Pearson, Ross D. Hannan, Luc Furic	2016	61
6	The dual inhibition of RNA Pol I transcription and PIM kinase as a new therapeutic approach to treat advanced prostate cancer European Journal of Cancer ·Richard J. Rebello, Eric Kusnadi, Donald P. Cameron, Helen Pearson, Rom Mit, Jennifer R. Devlin, Denis Drygin, Abbe R. Clark, Lisa A. Porter, 光司坂本, Shahneen Sandhu, Gail P. Risbridger, Richard B. Pearson, Ross D. Hannan, Luc Furic	2016	10
7	Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling Oncotarget ·Jaclyn Quin, Keefe T. Chan, Jennifer R. Devlin, Donald P. Cameron, Jeannine Diesch, Carleen Cullinane, Jessica Ahern, Amit Khot, Nadine Hein, Amee J. George, Katherine M. Hannan, Gretchen Poortinga, Karen E. Sheppard, Kum Kum Khanna, Ricky W. Johnstone, Denis Drygin, Grant A. McArthur, Richard B. Pearson, Elaine Sanij, Ross D. Hannan	2016	79
8	Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma Cancer Discovery ·Jennifer R. Devlin, Katherine M. Hannan, Nadine Hein, Carleen Cullinane, Eric Kusnadi, Pui Yee Ng, Amee J. George, Jake Shortt, Megan J. Bywater, Gretchen Poortinga, Elaine Sanij, Jian Kang, Denis Drygin, Sean O’Brien, Ricky W. Johnstone, Grant A. McArthur, Ross D. Hannan, Richard B. Pearson	2015	91
9	Targeting Protein Kinase CK2 Suppresses Prosurvival Signaling Pathways and Growth of Glioblastoma Clinical Cancer Research ·Ying Zheng, Braden C. McFarland, Denis Drygin, Hao Yu, Susan L. Bellis, Hyun Soo Kim, Markus Bredel, Etty Benveniste	2013	114
10	Targeting the nucleolus for cancer-specific activation of p53 Drug Discovery Today ·Denis Drygin, Sean O’Brien, Ross D. Hannan, Grant A. McArthur, Daniel D. Von Hoff	2013	37
11	CK2 Inhibitor CX-4945 Suppresses DNA Repair Response Triggered by DNA-Targeted Anticancer Drugs and Augments Efficacy: Mechanistic Rationale for Drug Combination Therapy Molecular Cancer Therapeutics ·Adam Siddiqui-Jain, Joshua Bliesath, 董天鹅, Mayuko Omori, Nanni Huser, Nicole Streiner, Caroline B. Ho, Kenna Anderes, Chris Proffitt, Sean O’Brien, John K. C. Lim, Daniel D. Von Hoff, David M. Ryckman, William G. Rice, Denis Drygin	2012	86
12	Novel potent dual inhibitors of CK2 and Pim kinases with antiproliferative activity against cancer cells Bioorganic & Medicinal Chemistry Letters ·Fabrice Pierre, K A Shittu, Zeinab Hossen Ali, Adam Siddiqui-Jain, 董天鹅, Nicole Streiner, Denis Drygin, Mustapha Haddach, Sean O’Brien, William G. Rice, David M. Ryckman	2012	28
13	Protein kinase CK2 modulates IL-6 expression in inflammatory breast cancer Biochemical and Biophysical Research Communications ·Denis Drygin, Caroline B. Ho, Mayuko Omori, Joshua Bliesath, Chris Proffitt, Rachel Rice, Adam Siddiqui-Jain, Sean O’Brien, Claire Padgett, John K. C. Lim, Kenna Anderes, William G. Rice, David M. Ryckman	2011	57
14	7-(4H-1,2,4-Triazol-3-yl)benzo[c][2,6]naphthyridines: A novel class of Pim kinase inhibitors with potent cell antiproliferative activity Bioorganic & Medicinal Chemistry Letters ·Fabrice Pierre, Eric Stefan, Huang Oiu-fu, Zeinab Hossen Ali, K A Shittu, Adam Siddiqui-Jain, 董天鹅, Nicole Streiner, Denis Drygin, Mustapha Haddach, Sean O’Brien, Kenna Anderes, David M. Ryckman	2011	46
15	Synthesis and SAR of inhibitors of protein kinase CK2: Novel tricyclic quinoline analogs Bioorganic & Medicinal Chemistry Letters ·Mustapha Haddach, Fabrice Pierre, K A Shittu, 昌輝高岡, Jerome Michaux, Eric Stefan, W. Rückert, Michael K. Schwaebe, Peter Chua, Adam Siddiqui-Jain, 董天鹅, Denis Drygin, Sean O’Brien, William G. Rice, David M. Ryckman	2011	15
16	Targeting RNA Polymerase I with an Oral Small Molecule CX-5461 Inhibits Ribosomal RNA Synthesis and Solid Tumor Growth Cancer Research ·Denis Drygin, Amy Lin, Josh Bliesath, Caroline B. Ho, Sean O’Brien, Chris Proffitt, Mayuko Omori, Mustapha Haddach, Michael K. Schwaebe, Adam Siddiqui-Jain, Nicole Streiner, Jaclyn Quin, Elaine Sanij, Megan J. Bywater, Ross D. Hannan, David M. Ryckman, Kenna Anderes, William G. Rice	2010	462
17	CX-4945, an Orally Bioavailable Selective Inhibitor of Protein Kinase CK2, Inhibits Prosurvival and Angiogenic Signaling and Exhibits Antitumor Efficacy Cancer Research ·Adam Siddiqui-Jain, Denis Drygin, Nicole Streiner, Peter Chua, Fabrice Pierre, Sean O’Brien, Josh Bliesath, Mayuko Omori, Nanni Huser, Caroline B. Ho, Chris Proffitt, Michael K. Schwaebe, David M. Ryckman, William G. Rice, Kenna Anderes	2010	421
18	Anticancer Activity of CX-3543: A Direct Inhibitor of rRNA Biogenesis Cancer Research ·Denis Drygin, Adam Siddiqui-Jain, Sean O’Brien, Michael K. Schwaebe, Amy Lin, Josh Bliesath, Caroline B. Ho, Chris Proffitt, Katy Trent, Jeffrey P. Whitten, John K. C. Lim, Daniel D. Von Hoff, Kenna Anderes, William G. Rice	2009	462
19	Quarfloxin (CX-3543) disrupts the Nucleolin/ rDNA quadruplex complexes, inhibits the elongation by RNA Polymerase I and exhibits potent antitumor activity in models of cancer Cancer Research ·Denis Drygin, S. Cabat, William G. Rice, Sean O’Brien, Michael K. Schwaebe, Amy Lin, Caroline B. Ho, Katy Trent	2008	6
20	Induction of Toll-like Receptors and NALP/PAN/PYPAF Family Members by Modified Oligonucleotides in Lung Epithelial Carcinoma Cells Oligonucleotides ·Denis Drygin, Seongjoon Koo, Ranjan J. Perera, Stephen Barone, C. Frank Bennett	2005	6

About Denis Drygin

Denis Drygin is a scholar working on Pathology and Forensic Medicine, Molecular Biology, Oncology, Cancer Research and Organic Chemistry, having authored 41 papers that have together received 2.7k indexed citations. Recurring topics across this work include RNA modifications and cancer (15 papers), Cancer-related Molecular Pathways (7 papers), Cancer Mechanisms and Therapy (6 papers), RNA and protein synthesis mechanisms (6 papers), Ubiquitin and proteasome pathways (5 papers), DNA Repair Mechanisms (4 papers), PI3K/AKT/mTOR signaling in cancer (4 papers) and DNA and Nucleic Acid Chemistry (4 papers). The work is most often cited by research in Molecular Biology (2.2k citations), Oncology (600 citations), Cancer Research (232 citations), Genetics (138 citations) and Pathology and Forensic Medicine (215 citations). Denis Drygin has collaborated with scholars based in United States, Australia and United Kingdom. Frequent co-authors include William G. Rice, Sean O’Brien, Adam Siddiqui-Jain, Ingrid Grummt, Kenna Anderes, Chris Proffitt, Caroline B. Ho, David M. Ryckman, Michael K. Schwaebe and Josh Bliesath. Their work appears in journals such as Cancer Research, Blood, Molecular Cancer Therapeutics, Bioorganic & Medicinal Chemistry Letters and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact